CASIA OpenIR  > 中国科学院分子影像重点实验室
Advanced nasopharyngeal carcinoma: pre-treatment prediction of progression based on multi-parametric MRI radiomics
Zhang, Bin1,2; Ouyang, Fusheng3; Gu, Dongsheng4; Dong, Yuhao5; Zhang, Lu5; Mo, Xiaokai5; Huang, Wenhui5; Zhang, Shuixing1,2
Source PublicationONCOTARGET
2017-09-22
Volume8Issue:42Pages:72457-72465
SubtypeArticle
AbstractWe aimed to investigate the potential of radiomic features of magnetic resonance imaging (MRI) to predict progression in patients with advanced nasopharyngeal carcinoma (NPC). One hundred and thirteen consecutive patients (01/2007-07/2013) (training cohort: n = 80; validation cohort: n = 33) with advanced NPC were enrolled. A total of 970 initial features were extracted from T2-weighted (T2-w) (n = 485) and contrast-enhanced T1-weighted (CET1-w) MRI (n = 485) for each patient. We used least absolute shrinkage and selection operator (Lasso) method to select features that were most significantly associated with the progression. The selected features were used to construct radiomics-based models and the predictive performance of which were assessed with respect to the area under the curve (AUC). As a result, eight features significantly associated with the progression of advanced NPC were identified. In the training cohort, a radiomic model based on combined CET1-w and T2-w images (AUC: 0.886, 95% CI: 0.815-0.956) demonstrated better prognostic performance than models based on CET1-w (AUC: 0.793, 95% CI: 0.698-0.889) or T2-w images alone (AUC: 0.813, 95% CI: 0.721-0.904). These results were confirmed in the validation cohort. Accordingly, MRI-based radiomic biomarkers present high accuracy in the pre-treatment prediction of progression in advanced NPC.
KeywordImaging Biomarkers Nasopharyngeal Carcinoma Progression Radiomics
WOS HeadingsScience & Technology ; Life Sciences & Biomedicine
DOI10.18632/oncotarget.19799
WOS KeywordCELL LUNG-CANCER ; RADIOTHERAPY ; FEATURES ; GLIOBLASTOMA ; RECURRENCE ; IMAGES ; PET
Indexed BySCI
Language英语
Funding OrganizationNational Scientific Foundation of China(81571664) ; Science and Technology Planning Project of Guangdong Province(2014A020212244 ; 2016A020216020)
WOS Research AreaOncology ; Cell Biology
WOS SubjectOncology ; Cell Biology
WOS IDWOS:000411509400090
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/20736
Collection中国科学院分子影像重点实验室
Affiliation1.Jinan Univ, Med Imaging Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
2.Jinan Univ, Inst Mol & Funct Imaging, Guangzhou, Guangdong, Peoples R China
3.First Peoples Hosp Shunde, Dept Radiol, Foshan, Peoples R China
4.Chinese Acad Sci, Key Lab Mol Imaging, Beijing, Peoples R China
5.Guangdong Acad Med Sci, Dept Radiol, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
Recommended Citation
GB/T 7714
Zhang, Bin,Ouyang, Fusheng,Gu, Dongsheng,et al. Advanced nasopharyngeal carcinoma: pre-treatment prediction of progression based on multi-parametric MRI radiomics[J]. ONCOTARGET,2017,8(42):72457-72465.
APA Zhang, Bin.,Ouyang, Fusheng.,Gu, Dongsheng.,Dong, Yuhao.,Zhang, Lu.,...&Zhang, Shuixing.(2017).Advanced nasopharyngeal carcinoma: pre-treatment prediction of progression based on multi-parametric MRI radiomics.ONCOTARGET,8(42),72457-72465.
MLA Zhang, Bin,et al."Advanced nasopharyngeal carcinoma: pre-treatment prediction of progression based on multi-parametric MRI radiomics".ONCOTARGET 8.42(2017):72457-72465.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zhang, Bin]'s Articles
[Ouyang, Fusheng]'s Articles
[Gu, Dongsheng]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zhang, Bin]'s Articles
[Ouyang, Fusheng]'s Articles
[Gu, Dongsheng]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zhang, Bin]'s Articles
[Ouyang, Fusheng]'s Articles
[Gu, Dongsheng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.